MCPH1, also known as BRIT1, has recently been identified as a novel key regulatory gene of the DNA damage response pathway. MCPH1 is located on human chromosome 8p23.1, where human cancers frequently show loss of heterozygosity. As such, MCPH1 is aberrantly expressed in many malignancies, including breast and ovarian cancers, and the function of MCPH1 has been implicated in tumor suppression. However, it remains poorly understood whether MCPH1 deficiency leads to tumorigenesis. Here, we generated and studied both 
INTRODUCTION
MCPH1 (also known as BRIT1) has been recently identified as a novel key regulator of the DNA damage response (DDR), DNA repair, and genomic instability. [1] [2] [3] It belongs to the BRCA1 C-terminal domain (BRCT) protein family, and contains three BRCT domains. 1, 2, 4 These domains are conserved protein-protein interaction modules involved in DDR. [5] [6] [7] [8] MCPH1 interacts with key partners (such as γ-H2AX, SWI/SNF, and SET), participating into DDR, chromosomal relaxation, and cell cycle checkpoint control. [9] [10] [11] [12] [13] [14] [15] [16] Importantly, our report demonstrates that Mcph1 is essential for DNA homologous recombination repair (HR) in the Mcph1 −/− mouse model. 17 Moreover, the cells derived from microcephaly patients (with MCPH1 inactivation) or Mcph1 −/− mice exhibit defective DNA repair and genomic instability, which are the hallmarks of many malignancies. 1, [17] [18] [19] Although these studies suggest that MCPH1 may act as a caretaker of the genome, one of the surveillance mechanisms of cancer, it remains to be determined whether MCPH1 plays a critical role in tumor suppression.
Recently, several lines of evidence have indicated that MCPH1 is aberrantly expressed in human cancers. 1, 3, [20] [21] [22] [23] [24] For example, low expression of MCPH1 exists iñ30% of breast cancers and positively correlates with higher grade tumors; 20 this suggests that MCPH1 deficiency may contribute to breast cancer. To further elucidate the tumor suppressive role of MCPH1, in this study we assessed tumor formation in both single Mcph1 −/− and Mcph1 −/− p53 −/− double knockout mice. Our data revealed that Mcph1 deficiency leads to tumor formation and accelerates the development of malignant lymphomas in p53 −/− mice.
More importantly, we demonstrate that Mcph1 deficiency promotes aneuploidy and defective DNA repairs, which is confirmed by rescue experiments. Therefore, our study using a knockout mouse model strongly supports that Mcph1 deficiency plays a critical role in tumor formation and development.
RESULTS

Mcph1 deficiency promotes long-latency tumor formation in mice
We have previously generated single Mcph1 −/− mice that have an increased propensity to malignancies. 17 To assess whether Mcph1 loss contributes to tumor susceptibility, we analyzed the viability of a cohort of Mcph1 +/+ (n = 38), Mcph1 +/− (n = 56), and Mcph1 −/− (n = 41) mice over a period of 2.5 years. The survival of Mcph1 −/− mice is significantly lower than that of the wild-type (WT) mice ( Figure 1A, 1B) . The results also showed that 17.1% of Mcph1 −/− mice succumbed to malignant tumors while only 5.3% of Mcph1 +/+ mice died from tumors ( Figure 1C) . Interestingly, Mcph1 +/− mice were approximately two times more likely to develop spontaneous tumors (8.9%) than WT ( Figure 1C ). Although most of Mcph1 −/− mice developed tumors after 1-2 years of age, a few tumors occurred as early as 6 months of age ( Figure 1C ). All tumors that evolved in Mcph1 −/− mice originated from lymph nodes (lymphoma) or ovaries (granuloma cell tumors) ( Figure 1D ). Therefore, this result demonstrates that Mcph1 loss in mice promotes tumor formation with long latency.
Mcph1 −/− p53 −/− mice display accelerated tumorigenesis
As we have shown, Mcph1 −/− mice developed tumors with long latency (Figure 1 ). We suspected that Mcph1 deficiency may not be very effective in promoting tumors because intact p53, a guardian of the genome, may suppress propagation of tumorigenesis. [25] [26] [27] To test this hypothesis, we crossed Mcph1 −/− into p53 −/− to generate Mcph1 −/− p53 −/− mice, which were confirmed by Southern blot analysis or PCR-based method (Figure 2A, 2B) . Typically, Mcph1 +/+ p53 −/− (n = 33) and Mcph1 +/− p53 −/− (n = 49) had an average life span of 16-18 weeks ( Figure 2C ). However, the medium survival time of Mcph1 −/− p53 −/− mice (n = 15) was only about 10 weeks ( Figure 2C , 2D, and Supplementary Table S1 ). The significant increase in tumor predisposition observed in Mcph1 −/− p53 −/− mice indicates that Mcph1 deficiency and p53 loss synergize to promote tumorigenesis.
Of all Mcph1 −/− p53 −/− mice analyzed, 80% died of lymphomas and three other mice of unidentified causes ( Figure 2E , Table S1 ). However, tumor spectra in (Table S1 ). These data indicate that Mcph1 deficiency mainly enhances susceptibility of malignant lymphomas in p53 −/− mice.
Mcph1 deficiency in the absence of p53 induces chromosomal aberrations and aneuploidy
To understand how Mcph1 deficiency contributes to tumorigenesis, we used a metaphase spread assay to examine chromosomal aberrations in primary lymphomas originated in mice. As shown in Figure 3A , irradiated Mcph1 −/− p53 −/− lymphoma cells harbored more structural aberrations, including chromosomal breaks and translocations, than the irradiated Mcph1 +/+ p53 −/− cells. Importantly, Mcph1 −/− p53 −/− cells exhibited more aneuploidy than Mcph1 +/+ p53 −/− ( Figure 3A) , which was further confirmed by spectral karyotyping (SKY) analysis (Table 1) Figure 4D ). After IR treatment, there were three major types of structural aberrations observed in Mcph1-deficient MEFs: chromatid breaks, chromosome breaks, and ring chromosomes (Table S2 ). Chromatid breaks were prominent in Mcph1 −/− and Mcph1 −/− p53 −/− MEFs (Table S2) . Moreover, asymmetric chromatid-type exchanges, which are the result of fusions between two or more broken chromatids and represent defective HR, were frequently detected in Mcph1 −/− p53 −/− , but rarely found in Mcph1 +/+ p53 −/− MEFs ( Figure 4E ). This suggests that HR is severely impaired in IR-treated, Mcph1-deficient MEFs.
To confirm that Mcph1 deficiency is indeed the cause of genomic instability in 
Mcph1 deficiency reduces DNA DSB repair
To determine how Mcph1 deficiency results in genomic instability, we evaluated DNA DSB by IR-induced foci formation (IRIF) of γ-H2AX and neutral-pH Comet assay. 28 Figure S3 ). IRIF of γ-H2AX were also evaluated 27 h after IR, at which time point the damaged DNA are regarded to be nearly repaired in cells with intact DDR. 30 
NHEJ activity is decreased in Mcph1-deficient MEFs
We further investigated whether NHEJ, another major repair pathway for DSBs, is impaired in Mcph1 −/− p53 −/− MEFs. To this end, we performed in vivo NHEJ assay. In line with previous studies, 1, 11 NHEJ activity in Mcph1 −/− MEFs was notably decreased as compared to Mcph1 +/+ MEFs ( Figures 6D, S7) . The level of NHEJ activity in Mcph1 −/− p53 −/− MEFs was also decreased as compared to Mcph1 +/+ p53 −/− MEFs although it remained similar level to Mcph1 +/+ MEFs. To further determine whether NHEJ-associated V(D)J recombination process is involved in lymphomagenesis, we examined developmental stages at which thymic lymphomas developed in Mcph1 −/− p53 −/− mice. We performed immunofluorescent staining of lymphoma using antibodies against CD4, CD8, CD44, and CD25, the molecular markers of thymocytes development. 33, 34 The analyses showed that lymphomas from 
DISCUSSION
In this study, we have generated and analyzed both Mcph1 −/− and Mcph1 −/− p53 −/− mice. By using our unique germline Mcph1 −/− mouse model, we have found that Mcph1 loss itself triggers long-latency tumor formation in mice. This phenomenon may be attributed to the fact that Mcph1 deficiency needs to cooperate with other aberrant tumor suppressors or oncoproteins to overcome the barrier of "guardian of the genome" to form a tumor. 35 Indeed, when we crossed Mcph1 −/− into p53 −/− mice, Mcph1 deficiency enhanced tumor susceptibility in p53-null background. Deficiency of other DDR proteins (e.g. BRCA1, 53BP1, H2AX, and NBS1) in p53-null background has also accelerated lymphomagenesis in mice, 25, 30, 36, 37 supporting our observation in Mcph1 −/− p53 −/− mice. Meanwhile, human MCPH1 is located on chromosome 8p23.1, a locus on which loss of heterozygosity is frequently observed in human cancers. A number of previous studies have shown that MCPH1 is aberrantly downregulated in breast and ovarian cancer, particularly in higher grade tumors. 1, 20, 21 Moreover, we have analyzed a large cohort of Oncomine datasets including TCGA data, which revealed that MCPH1's copy number and mRNA level are notably reduced in solid tumors ( Figure S9 ). [38] [39] [40] Thus, we provide convincing genetic evidence that Mcph1 may act as a novel tumor suppressor.
Mechanistically, our study demonstrates that Mcph1 deficiency promotes aneuploidy and causes defective DSB repairs, which together may contribute to increased tumor susceptibility in Mcph1 −/− p53 −/− mice. First, our data reveal that loss of Mcph1 leads to substantially increased aneuploidy in Mcph1 −/− p53 −/− lymphomas. Aneuploidy is a wellknown hallmark in cancers and it may arise from centrosome malfunction or defects in mitotic segregation. [41] [42] [43] [44] In fact, centrosome amplification has been reported in MCPH1-knockdown U2OS cells 45 and Mcph1 −/− DT40 cells 19 . Consistently, we observed centrosome hyper-amplification in Mcph1 −/− p53 −/− MEFs. Interestingly, the staining pattern of γ-tubulin, a centrosome marker, appears to be heterogeneous in Mcph1 −/− p53 −/− MEFs, which may be caused by increased centriole number associated with Mcph1 deficiency. Previous studies have also shown that loss of Mcph1 dysregulated Chk1 or Aurora A/plk1-associated mitotic pathways. 14, 45, 46 Therefore, Mcph1 deficiency causes abnormal communications between mitosis and centriole duplication, and thereby leads to centrosome hyper-amplification, which, in turn, promotes aneuploidy and ultimately tumorigenesis.
Second, our studies reveal that Mcph1 deficiency leads to defective DNA repairs and severe chromosomal aberrations in p53-null background, as indicated by foci formation assay, comet assay, metaphase spread assay and DNA repair assays. In consistent with previous reports, 1,9,11,12,17 we observed Mcph1 deficiency substantially decreased HR activity in Mcph1 −/− p53 −/− MEFs. Thus, it is possible this HR defects causes genomic instability and as a result, may contribute to tumorigenesis for the Mcph1 −/− p53 −/− mice. In fact, lines of evidence support the role of defective HR repair in promoting tumor formation; deletion/ mutations of HR repair genes commonly occur in many cancer types, e.g. BRCA1/2 in breast and ovarian cancer, 47, 48 RAD54 /CtIP in lymphoma and colon cancer, 49, 50 RAD51B in lipoma, 51 and RECQL4 in osteosarcoma 52 . In addition to defective HR repair, NHEJ repair is largely impaired in Mcph1 −/− p53 −/− MEFs as compared to p53-null MEFs, which is in line with previous studies. 1, 11 However, NHEJ may be not directly involved in lymphomagenesis of Mcph1 −/− p53 −/− mice since lymphoma in these mice originally formed around DN1/2 stage, slightly before the stage of NHEJ-directed V(D)J process. Consistent with our study, lymphomas developed in mice deleted for both NHEJ genes and p53 (ref. [53] [54] [55] are believed to be mainly induced by a failure of apoptosis due to absence of p53, leading to the inappropriate survival of potentially defective cells that were lymphomagenic, supporting NHEJ-associated abnormalities may be not involved in lymphomagenesis in p53-null mice.
Analysis of our single Mcph1 −/− mice shows that Mcph1 deficiency itself triggers longlatency tumor formation; it is possible that those cells with genomic instability induced by
Mcph1 deficiency is eliminated by p53 or other pathway-mediated apoptosis and few tumorigenesis occurs. When we cross Mcph1 −/− into p53 −/− mice, Mcph1 deficiency greatly enhances tumor susceptibility in p53-null background with increased aneuploidy and chromosomal structural aberrations. Here, p53 loss may attenuate apoptosis, allowing cells with severe chromosomal aberrations to survive and transform to tumor cells in the absence of Mcph1. These data together demonstrate that Mcph1 can cooperate with p53, a master tumor suppressor, to prevent tumor formation. In addition to its critical role in DDR signaling and DNA repair, recently, MCPH1 has been shown to be a novel regulator for p53 protein stability using human breast cancer cell lines. 56A MCPH1 can interact with MDM2 (murine double minute 2) and p53, and control p53 stability by regulating MDM2-mediated p53 ubiquitination. This post-translational modification of p53 is likely to be another mechanism by which MCPH1 functions as a tumor suppressor.
Of note, Mcph1 −/− p53 −/− mice mainly develop lymphoma, but not carcinomas (i.e. epithelial tumors), although both MCPH1 and p53 aberrations have been frequently observed in human carcinomas (including breast and ovarian cancer). 20, 57 Similarly, other studies have shown that carcinomas cannot be developed in p53 −/− mice or p53 −/− mice with deficiency of other DDR proteins (such as BRCA1, 53BP1, H2AX, and NBS1). 25, 30, 36, 37 This preferential bias of tumorigenesis may occur at least partially because of p53-null mutation in mice. In humans, p53-associated carcinomas mainly harbor point mutations, but not the large deletions (null status) of p53 (ref. 58 ). In fact, two p53 gain-of-function mutant mouse models, such as p53 R172H/− and p53 R270H/− , have been observed to frequently develop carcinomas. 57, 59 This demonstrates that gain of function of p53 mutants (regarding as "oncogenes"), but not the null mutation of p53, plays a key role in the development of carcinomas. In our current Mcph1 −/− p53 −/− mouse model, p53 is in a null background, lacking gain of function of p53 mutants, therefore, carcinomas have not been developed in Mcph1 −/− p53 −/− mice. Since MCPH1 aberrations are common events in several types of human carcinomas, it will be critical to evaluate Mcph1's role in carcinomas such as breast cancer using mouse models. In the future, we will exploit our epithelia-specific 
MATERIALS AND METHODS
Mice and genotyping
All mice were bred and maintained in a conventional animal facility under protocol AN-3575 approved by Baylor College of Medicine. Previously established Mcph1 −/− mice 17 were bred with p53 −/− mice 60 to generate Mcph1 −/− p53 −/− mice. Mice were monitored every other day for the development of tumors and other signs of poor health. Those that had difficulty breathing and a hunched back, or signs of thoracic congestion because of an enlarged thymus, were sacrificed within 1 day of detection of the problem and screened for tumors. 36 Genotyping was performed with Southern blot or a PCR-based method. For Southern blot, genomic DNA was digested with BamHI (New England BioLabs, Ipswich, MA, USA), and then hybridized with probes appropriate for Mcph1 or p53. For the PCR-based method, the primers used for Mcph1 and p53 were provided upon request.
Tumor histology and developmental staging
Tissues from solid tumors were stained with hematoxylin and eosin (H&E) according to a standard histological protocol, and examined under the microscope by experienced pathologists.
Lymphoma staging was determined according to the immunofluorescent staining of lymphocyte markers, as described previously with modifications. 61, 62 Before staining, Fc II/III receptors were blocked first by preincubation with anti-CD16/32 (Fc-Block, BD Biosciences, San Jose, CA, USA). Cell markers were then stained either directly (CD4-FITC, CD8-FITC; Sigma, St. Louis, MO, USA), or indirectly (CD44, CD25; Novus Biologicals, Littleton, CO, USA) in 1% BSA/PBS for 2 h at 4°C. The indirectly-stained slides were further incubated with goat-anti-mouse (or rabbit) IgG-Alexa Fluor 594 or Alexa Fluor 488 (Life Technologies, Carlsbad, CA, USA) for 2 h at 4°C. The slides were counterstained with DAPI, and finally observed microscopically. About ~1000 cells were counted in each slide from each lymphoma, and at least two lymphomas were used for each genotype. The experiments were duplicated for analysis.
Primary thymic lymphoma cells
Thymic lymphoma cells were isolated from Mcph1 +/+ , Mcph1 −/− , Mcph1 +/+ p53 −/− , and Mcph1 −/− p53 −/− mice and maintained in RPMI 1640 complete medium with 10 ng/ml of IL-2 (BioLegend, San Diego, CA, USA) at low passages (P<5 passages) for future use.
Metaphase spread assay
Metaphase spreads were performed as previously described. 63 Primary thymic lymphoma cells and MEFs were irradiated at the indicated doses. Cells were then treated with KaryoMax Colcemid (Life Technologies, Grand Island, NY, USA) for 2 h and metaphase spreads were prepared 3 h and/or 27 h after IR, according to a standard protocol. At least 30-50 metaphase spreads were analyzed for each case, and at least two pairs of lymphomas or MEFs from each genotype were used to repeat the experiments.
Spectral karyotyping (SKY) analysis
SKY analysis was carried out according to the manufacturer's protocol. 64 The cocktail of mouse chromosome paints was obtained from Applied Spectral Imaging (ASI, Vista, CA, USA). Chromosomes were counterstained with DAPI. For each case, a minimum of 10 metaphase cells was analyzed with SKY, and at least two lymphomas were used for each genotype.
Neutral-pH Comet assay
Neutral Comet assay was performed with the Trevigen's CometAssay kit (Trevigen, Gaithersburg, MD, USA) according to the manufacturer's instructions. MEFs were treated with or without IR (4Gy), and then subjected to Comet assay at 30 min or 27 h after IR. SYBR Green I-stained Comet images were captured with fluorescence microscopy. Tail moments were determined in at least 75 cells/slide with the Comet Assay IV software (Perceptive Instruments, Bury St Edmunds, UK). Data were collected from three independent experiments.
HR repair assay
DR-GFP/I-SceI-based HR repair assay was performed with transient transfection. Briefly, MEFs (5 x 10 6 cells) were seeded into 6-well plates and transfected with both DR-GFP and either of pCAGGS (mock plasmid), pEGFP-C1 (GFP-expressing plasmid), or pCBASce (ISceI-expressing plasmid) (1.25 μg each plasmid, totally 2.5μg/well). Forty-eight hours later, GFP + cells were detected with LSR II flow cytometry (Becton Dickinson, San Jose, CA). Data were analyzed with Flowjo Version 10 (Tree Star, Ashland, OR, USA). This experiment was repeated at least three times.
NHEJ activity assay
NHEJ activity assay was performed as described previously with minor modifications. 65 In this study, BamHI-cleaved pCSCMV-tdTomato was used as a target for NHEJ, and pEGFPC1 as a control plasmid. Briefly, MEFs were co-electroporated with pCSCMVtdTomato plasmid (Plasmid 30530, Addgene, Cambridge, MA, USA) digested with BamHI, which cleaves between the promoter and the tdTomato open reading frame, and pEGFP-C1 at 2.5 μg of DNA per 10 6 cells each. Cells were then cultured for 10-12 h. The counts of tdTomato-expressing and GFP-expressing cells were estimated with LSRFortessa (BD Biosciences, San Jose, CA, USA), and data were analyzed with FlowJo Version 10 (Tree Star, Ashland, OR, USA). Two pairs of MEFs for each genotype were used, and the experiments were duplicated for analysis.
Immunofluorescent staining
IR-induced foci formation assay was performed as described previously. 1 The primary antibodies used here were anti-GST-Mcph1 (gift from Dr. Shiaw-Yih Lin at MD Anderson Cancer Center, Houston, Texas), anti-γ-H2AX (Bethyl Laboratories, Montgomery, TX, USA; Cat# A300-081), anti-Rad51 (Santa Cruz Biotechnology, Santa Cruz, CA, USA; Cat# sc-8349), and anti-Brca2 (Santa Cruz Biotech, Santa Cruz, CA, USA; Cat# sc-28235). Centrosome analysis was performed as described elsewhere, 66 with primary antibody anti-γ-Tubulin (Sigma, St. Louis, MO, USA; Cat# T6557). Centrosome numbers were counted in approximately 300 cells from at least 10 fields per type of cells. These experiments were repeated at least three times.
Flow Cytometry
MEFs were treated with or without the indicated doses of IR, collected by trypsinization, fixed by 75% ethanol, and kept at −20°C for at least 2 h. After centrifugation, MEFs were stained with propiduim iodide (PI, 2 μg/mL in PBS) and RNase A (10 μg/mL). FACS analysis was performed with FACScan (BD, San Jose, CA, USA) and the data analyzed with Flowjo software (Ashland, OR, USA).
BrdU incorporation assay
The BrdU incorporation assay was performed with the BrdU labeling and detection kit (Roche, Pleasanton, CA, USA), according to the manufacturer's instructions. BrdU-positive cells were stained intensely brown, and BrdU incorporation rate of the entire population was then scored. About 500 cells were counted for each case, and the data were analyzed from three independent experiments.
Statistical analysis
Cultured cell-based assays were repeated at least two or three times in triplicate and the significance was assessed with unpaired Student t-test. Kaplan-Meier survival curve and log-rank test were used for survival analysis. Error bars show s.d. P< 0.05 was considered statistically significant. Normal thymus is composed of a dark-staining basophilic cortex and a light-staining eosinophilic medulla (i, iii). Normal cortex contains numerous densely packed lymphocytes, and the medulla has fewer lymphocytes and more thymic corpuscles (blue arrows). However, there is no definite cortex and medulla structure in thymic lymphoma from Mcph1 −/− p53 −/− mice (ii, iv), and the entire region is composed of densely packed lymphocytes and infiltrated with more blood vessels (black arrows). Thymic corpuscles are almost disrupted and infiltrated with more lymphocytes (blue asterisks in panel iv). 
